Tocilizumab – Page 58 – Communicable Diseases Research

Inflammatory cytokine depletion in severe coronavirus disease 2019 infectious pneumonia A case report

중증 코로나바이러스 감염증 2019 감염성 폐렴에서 염증성 사이토카인 고갈 증례보고

Case Reports

Published on 2020-12-042022-09-12
Journal: Medicine [Category] MERS, SARS, 진단,

Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data

Pharmacology

Published on 2020-12-032022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] 95% CI Acute kidney injury Adverse adverse (side) effects Adverse drug reaction ALS analyzed Anemia caution cerebrospinal fluid chloroquine/hydroxychloroquine Corona corona virus disease-19 (COVID-19) COVID-19 patient COVID-19 patients Dexamethasone distribution drug eosinophilia Hepatitis hepatotoxic hospital hospitalized patient hyponatremia incidence incidence rate induce Laboratory leukocyte Lopinavir-ritonavir medication neutropenia non-COVID-19 patient Non-COVID-19 patients pandemic patients patients with COVID-19 pharmacovigilance pharmacovigilance process Program reaction reflected serious adverse drug reaction signal Spain Suspected Tertiary the SARS-CoV-2 Thromboembolic events Tocilizumab
[DOI] 10.3389/fphar.2020.602841 PMC 바로가기 [Article Type] Pharmacology

Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab

토실리주맙으로 치료한 COVID-19 폐렴 환자 6명의 신장 이식 사례 시리즈

Article

Published on 2020-12-012022-09-11
Journal: Transplant infectious disease : an official journa [Category] MERS, SARS, 진단, 치료제,

Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial

심각하고 치명적인 COVID-19가 있는 성인의 피하 토실리주맙: 전향적 공개 표지 비통제 다기관 시험

Clinical Trial

Published on 2020-12-012022-09-12
Journal: International immunopharmacology [Category] MERS, SARS, 임상, 진단,

[키워드] added all-cause mortality rate Antiviral approved body temperature changes in clinical parameter concerning coronavirus coronavirus disease COVID-19 COVID-19 pandemic COVID-19 patients Critical Critical disease dose early stage Endpoint enrolled immunomodulator immunomodulatory IMPROVE in both group interleukin interleukin 6 Laboratory male Most patient multicenter Multicenter trial occurred Open-label oral temperature oxygen saturation oxygen-support Oxygenation Patient patients died Potential reduce reported required Respiratory failure respiratory rate risk of death Serious Adverse Event Seven Severe patient severe patients Significant significantly standard care Subcutaneous subjects Therapeutic approach therapy Tocilizumab tocilizumab administration variable
[DOI] 10.1016/j.intimp.2020.107102 PMC 바로가기 [Article Type] Clinical Trial

Natural history of COVID-19 and therapeutic options

Review

Published on 2020-12-012023-07-13
Journal: Expert review of clinical immunology [Category] SARS,

[키워드] Azithromycin Care COVID humans Hydroxychloroquine pathophysiology Remdesivir SARS-CoV-2 Tocilizumab Treatment
[DOI] 10.1080/1744666X.2021.1847640 [Article Type] Review

Heart transplant recipient patient with COVID-19 treated with tocilizumab

Case Reports

Published on 2020-12-012023-07-13
Journal: Transplant infectious disease : an official journa [Category] SARS,

[키워드] COVID-19 heart transplant Pneumonia Tocilizumab
[DOI] 10.1111/tid.13380 [Article Type] Case Reports

Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness

심각한 COVID-19 질병을 치료하기 위해 토실리주맙을 투여받는 환자의 사망률을 예방하는 코르티코스테로이드의 유익한 효과

Article

Published on 2020-12-012022-09-12
Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 진단,

Safety and Efficacy of Tocilizumab in the Treatment of Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia: A Retrospective Cohort Study

Original Article

Published on 2020-12-012023-06-16
Journal: Indian journal of medical microbiology [Category] MERS, SARS,

[키워드] coronavirus COVID-19 cytokine release storm severe acute respiratory syndrome coronavirus-2 Tocilizumab
[DOI] 10.4103/ijmm.IJMM_20_298 PMC 바로가기 [Article Type] Original Article

High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19

높은 혈청 IL-6 값은 COVID-19 진단을 받은 환자의 사망 위험과 폐렴의 중증도를 증가시킵니다

Article

Published on 2020-12-012022-09-11
Journal: Molecular immunology [Category] MERS, SARS, 바이오마커, 진단,

[키워드] 95 % CI Analysis analyzed Asymptomatic Blood Cohort COVID-19 COVID-19 diagnosis COVID-19 pneumonia CURB CURB-65 CURB-65 score cut-off cut-off point defined diagnosed with COVID-19 Diagnosis diagnosis of COVID-19 died disease severity effective heterogeneous ICU ICU admission IL-6 IL-6 level IL-6 receptor IL-6 serum levels Laboratory laboratory findings lead mechanical ventilation Mortality parameter Patient patient mortality patients patients with COVID-19 Pneumonia prognostic biomarker Prognostic biomarkers receptor antagonist risk ROC Curve serum Serum IL-6 Serum level serum levels severe disease severe pneumonia severe symptoms severity starting the disease Tocilizumab treated
[DOI] 10.1016/j.molimm.2020.10.006 PMC 바로가기 [Article Type] Article

Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review

COVID-19에 대한 면역 요법, 항바이러스 요법 또는 둘 다: 체계적인 검토

Article

Published on 2020-12-012022-09-11
Journal: Drugs [Category] MERS, SARS, 진단, 치료제,

[키워드] Admission Anakinra analysed Antiviral antivirals article articles Baricitinib case reports Characteristics Chloroquine Clinical features clinical impact Colchicine combination therapy control group COVID-19 COVID-19 patient cumulative Cytokine release syndrome database deaths Dexamethasone discharge disease dysregulation Efficacy eligibility criteria English language Evidence exclusion explain Favipiravir first stage Google Scholar helping High-flow oxygen Hydroxychloroquine identify immune immune dysregulation immune response Inclusion Inconclusive indicated Infection intensive care intensive care unit intensive care unit admission item itolizumab large trial Loading dose Lopinavir Lopinavir/ritonavir management medRxiv meta-analyses Mortality Open-label oxygen Pathogenesis pathogenesis of COVID-19 pathogenic mechanism patients primary end point PRISMA Randomised controlled trials rationale RCTs reduced reduction Remdesivir removal reported Reporting requiring high-flow oxygen retrospective review Ritonavir ruxolitinib sarilumab SARS-CoV-2 SARS-COV-2 infection significantly siltuximab supportive therapy systematic review systematic reviews the disease the SARS-CoV-2 therapeutic therapeutic agent Therapeutic approach therapeutic approaches therapy Time to recovery Tocilizumab Treatment treatment of COVID-19 patients Trial trials triggered USA was performed were excluded
[DOI] 10.1007/s40265-020-01421-w PMC 바로가기 [Article Type] Article